Allogene Therapeutics ALLO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.76M+9.0% | -$190.89M+10.0% | -$212.02M+10.5% | -$236.91M+6.1% | -$252.32M+2.0% | ||
| $12.13M-1.9% | $12.36M-1.4% | $12.54M-0.9% | $12.65M-4.1% | $13.18M-3.3% | ||
| $33.74M-10.4% | $37.64M-11.2% | $42.39M-10.0% | $47.12M-9.4% | $51.99M+0.5% | ||
| —— | —— | -$1.83M+77.1% | -$7.99M-958% | -$755K-40.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$654K+79.9% | -$3.26M+23.8% | ||
| $1.29M+13.4% | $1.14M+26.0% | $901K+37.1% | $657K+58.3% | $415K+60.2% | ||
| -$7.87M-4.9% | -$7.5M-1.5% | -$7.39M-2.3% | -$7.22M-4.2% | -$6.93M-9.9% | ||
| -$109.23M+26.8% | -$149.25M+5.7% | -$158.35M+8.4% | -$172.77M+12.4% | -$197.33M+1.5% | ||
| $296K-23.3% | $386K-40.0% | $643K-22.4% | $829K+5.6% | $785K+13.1% | ||
| $189.73M+37.2% | $138.26M-11.9% | $156.85M-47.3% | $297.88M-9.9% | $330.57M-8.5% | ||
| $15.62M— | $0— | —— | —— | —— | ||
| $59.8M-37.4% | $95.56M-18.2% | $116.88M— | —— | —— | ||
| —— | —— | —— | —— | $11.54M+652% | ||
| $37.29M+23.6% | $30.16M+7.5% | $28.04M+10.0% | $25.48M-80.2% | $129.02M+10.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$21.63M-896% | $2.72M+0.3% | $2.71M-24.7% | $3.6M-84.5% | $23.19M+3.9% | ||
| -$7.87M-4.9% | -$7.5M-1.5% | -$7.39M-2.3% | -$7.22M-4.2% | -$6.93M-9.9% | ||
| $1.29M+13.4% | $1.14M+26.0% | $901K+37.1% | $657K+58.3% | $415K+60.2% | ||
| -$4.99M-54.2% | -$3.24M— | —— | —— | —— | ||
| $3.8M-10.0% | $4.22M-16.4% | $5.05M-13.3% | $5.83M-15.0% | $6.86M-17.9% | ||
| $12.93M0.0% | $12.92M+0.3% | $12.88M+0.2% | $12.85M+1.5% | $12.66M+1.3% | ||
| $249.82M+6.7% | $234.2M-14.6% | $274.38M-14.9% | $322.27M-16.4% | $385.69M-10.8% | ||
| —— | —— | —— | —— | —— | ||
| $4K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $279K— | —— | ||
| -$7.87M-4.9% | -$7.5M-1.5% | -$7.39M-2.3% | -$7.22M-4.2% | -$6.93M-9.9% | ||
| $4.29M-1.4% | $4.36M-1.6% | $4.42M-8.7% | $4.85M-7.5% | $5.24M-0.5% | ||
| -$109.53M+26.8% | -$149.63M+5.9% | -$158.99M+8.4% | -$173.6M+12.4% | -$198.12M+1.4% | ||
| -$109.53M+26.8% | -$149.63M+5.9% | -$158.99M+8.4% | -$173.6M+12.4% | -$198.12M+1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.